Yahoo Finance

NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk

BOSTON, MA, June 12, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data ...
Yahoo Finance

NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1

Philadelphia, PA, April 30, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 ...
manilatimes

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796

NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic ...
manilatimes

NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination with a GLP-1 Receptor Agonist

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced ...
FierceBiotech

NodThera's NLRP3 inhibitor shows further anti-inflammatory promise in phase 1b/2a obesity trial

NodThera’s NLRP3 inhibitor has already proved its worth against Novo Nordisk’s blockbuster obesity drug in preclinical trials. Now, an early readout from a study in humans with obesity has again ...
FierceBiotech

NodThera Parkinson's drug almost matches Wegovy for weight loss in mice, with bonus heart benefits

NodThera’s lead clinical-stage drug for Parkinson’s disease is almost as effective at inducing weight loss as Novo Nordisk’s blockbuster GLP-1 receptor agonist Wegovy, according to new data. In an ...